BioSpace News Archive

Celldex Therapeutics, Inc. announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET.

Tempest Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.

Singular Genomics Systems Inc. and TwinStrand Biosciences, Inc. announced a collaboration to develop highly sensitive next generation sequencing solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease detection.

Lipocine Inc., a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented “LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy” at the 2022 Epilepsy Foundation Pipeline Conference.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, announced the award of eleven research grants to universities under the company’s twelfth Annual Research Award Program.

Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Mirati Therapeutics presented the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced its HTG EdgeSeq technology was highlighted in multiple scientific abstracts at the 2022 American Society of Clinical Oncology (ASCO) conference held in Chicago, Illinois.

Gilead Sciences, Inc. (Nasdaq: GILD) today presented final data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease.